Cardiac bio-scaffold company Ventrix said it launched a trial of its VentriGel biomaterial scaffold designed to repair cardiac tissue in patients who’ve suffered a myocardial infarction.
The phase 1, open-label trial is slated to enroll patients who’ve experienced their 1st myocardial infarction in the past 3 years and show signs of left ventricular dysfunction, according to the San Diego, Calif.-based company.
“We have demonstrated statistically significant efficacy for VentriGel in our preclinical studies and are hopeful to see the benefits translated to patients. For people who have survived heart attacks, congestive heart failure is a common, costly and potentially fatal condition, and treatment options are severely limited. With our approach, we hope to alter the negative remodeling post-MI that leads to heart failure,” chief medical officer Dr. Paul Chamberlin said in a press release.
The trial is set to enroll patients at 3 U.S. centers, examining the safety and feasibility of the cardiac bio-gel delivered via catheter, Ventrix said. Secondary endpoints for the trial will be efficacy variables for stopping the progression of heart failure.
“VentriGel is a novel biomaterial that has been specifically designed for cardiac repair. The initiation of this study is an important milestone for Ventrix as we work to advance a new option for patients suffering from the effects of a heart attack,” CEO Adam Kinsey said in a press release.
The post Ventrix launches cardiac scaffolding trial appeared first on MassDevice.
from MassDevice http://ift.tt/1F4FIxf
Cap comentari:
Publica un comentari a l'entrada